Archives

  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-08
  • 2025-07
  • 2025-06

    • Angiotensin 1/2 (2-7): Molecular Insights and Next-Genera...

    2025-10-20

    Angiotensin 1/2 (2-7): Molecular Insights and Next-Generation Applications in Cardiovascular and Infectious Disease Models

    Introduction

    Advances in peptide research have propelled the renin-angiotensin system (RAS) peptide fragment Angiotensin 1/2 (2-7) (sequence: ARG-VAL-TYR-ILE-HIS-PRO) to the forefront of cardiovascular and infectious disease modeling. While existing literature has largely focused on the peptide’s roles in blood pressure regulation and vasoconstriction, the scientific community is now poised to leverage its unique biochemical properties for elucidating complex pathophysiological mechanisms. This article provides a comprehensive, molecular-level exploration of Angiotensin 1/2 (2-7), integrating new findings on its structural dynamics, receptor interactions, and translational potential in emerging disease frameworks. Our analysis moves beyond prior summaries, engaging with both canonical and non-canonical RAS activity and the implications for next-generation research models.

    Biochemical and Structural Properties

    Sequence and Synthesis

    Angiotensin 1/2 (2-7) is an N-terminal peptide fragment derived from angiotensin I and II, composed of six amino acids: ARG-VAL-TYR-ILE-HIS-PRO. This fragment, often referred to as the ARG-VAL-TYR-ILE-HIS-PRO peptide, is produced via enzymatic cleavage during RAS activation. Renin initiates the cascade by converting angiotensinogen to angiotensin I, followed by angiotensin-converting enzyme (ACE) processing to generate angiotensin II, from which Angiotensin 1/2 (2-7) emerges through additional peptidase activity.

    Physicochemical Attributes

    • Molecular Formula: C37H57N11O8
    • Molecular Weight: 783.92 Da
    • Solubility: ≥2.78 mg/mL in ethanol, ≥46.6 mg/mL in water, ≥78.4 mg/mL in DMSO
    • Purity: 99.80% (HPLC and MS validated)
    • Storage: -20°C for optimal stability; solutions recommended for short-term use

    These attributes ensure Angiotensin 1/2 (2-7) is suitable for diverse experimental designs, particularly those requiring high-fidelity peptide function and solubility in aqueous and organic media.

    Mechanism of Action of Angiotensin 1/2 (2-7)

    Canonical RAS Function and Signaling

    Within the classic RAS pathway, peptide fragments such as Angiotensin 1/2 (2-7) modulate vascular tone and fluid homeostasis. Angiotensin II primarily exerts its effects via the type 1 angiotensin II receptor (AT1R), triggering vasoconstriction, aldosterone release, and sodium retention in the distal nephron. Angiotensin 1/2 (2-7), by virtue of its sequence and structural features, is believed to retain partial agonist activity at these receptors while exhibiting a distinct binding profile compared to full-length angiotensin II.

    Moreover, its role as an angiotensin-converting enzyme (ACE) substrate positions Angiotensin 1/2 (2-7) at a critical junction for understanding the nuanced regulation of blood pressure and electrolyte balance. The peptide’s ability to stimulate aldosterone release and promote sodium reabsorption further underscores its importance for blood pressure regulation research and hypertension model development.

    Non-Canonical Interactions and Pathophysiological Implications

    Recent studies have broadened our perspective on angiotensin peptide fragments. Notably, Oliveira et al. (2025, Int. J. Mol. Sci.) demonstrated that shorter angiotensin peptides, including N-terminal deletions like Angiotensin 1/2 (2-7), can significantly enhance the binding of the SARS-CoV-2 spike protein to the AXL receptor. This mechanism is distinct from the classical ACE2-mediated viral entry pathway and suggests that Angiotensin 1/2 (2-7) may play a previously unrecognized role in infectious disease pathogenesis.

    "While a longer peptide, angiotensin I (1–10), did not affect the spike–AXL binding, shorter lengths of angiotensin peptides exhibited enhancing effects... N-terminal deletions of angiotensin (1–7) to angiotensin (2–7) produced peptides with a more potent ability to enhance spike–AXL binding.”
    —Oliveira et al., 2025

    Such findings open new avenues for using Angiotensin 1/2 (2-7) as a molecular probe in infectious disease research, particularly for exploring viral-host interactions beyond the established RAS framework.

    Comparative Analysis with Alternative Methods and Peptides

    Distinctiveness of Angiotensin 1/2 (2-7) Among RAS Peptides

    While full-length angiotensin I and II are well-characterized in hypertension and cardiovascular disease models, their shorter derivatives—especially Angiotensin 1/2 (2-7)—offer several unique advantages:

    • Enhanced Selectivity: The truncated structure may confer receptor selectivity and distinct downstream signaling, enabling more precise dissection of pathway-specific effects.
    • Improved Solubility and Handling: High aqueous solubility and 99.80% purity, as found in the ApexBio A1050 Angiotensin 1/2 (2-7) reagent, surpass many alternative RAS peptides.
    • Novel Pathophysiological Insights: Its potent modulation of spike–AXL interactions, as revealed by Oliveira et al., is not seen with longer angiotensin peptides.

    Contrasting with Prior Content

    Previous articles, such as “Angiotensin 1/2 (2-7): Mechanistic Insights and Strategic...”, have primarily emphasized the peptide’s established role in blood pressure and renin-angiotensin signaling. Our present analysis, in contrast, delves deeper into the molecular determinants of receptor selectivity, the impact of peptide truncation on biological activity, and the intersection with viral pathogenesis—thereby extending the dialogue to next-generation research needs. Moreover, unlike “Angiotensin 1/2 (2-7): Precision Tool for Blood Pressure ...”, which focuses on practical research applications, our article integrates recent molecular findings and their translational implications for infectious and cardiovascular disease models.

    Advanced Applications in Disease Modeling

    Cardiovascular Disease and Hypertension Research

    The high-purity, validated vasoconstrictor peptide Angiotensin 1/2 (2-7) serves as a powerful tool for dissecting the nuances of the renin-angiotensin signaling pathway. Its unique sequence and bioactivity enable researchers to:

    • Model partial agonism and antagonism at AT1R and AT2R, crucial for hypertension research.
    • Isolate the contribution of individual RAS fragments to aldosterone release and sodium homeostasis.
    • Explore peptide-receptor interactions using advanced pharmacological assays and structural biology techniques.

    By leveraging Angiotensin 1/2 (2-7) in these contexts, scientific teams can build more granular cardiovascular disease models, advancing both mechanistic insight and therapeutic discovery.

    Infectious Disease and SARS-CoV-2 Models

    Perhaps most intriguingly, Angiotensin 1/2 (2-7) is now implicated in the modulation of viral spike protein interactions, particularly with the AXL receptor. As demonstrated in the referenced IJMS 2025 paper, this peptide fragment enhances spike–AXL binding more robustly than its longer or alternative counterparts. This finding:

    • Suggests a role for Angiotensin 1/2 (2-7) in viral entry and pathogenesis beyond classical ACE2-mediated mechanisms.
    • Supports the use of this peptide in high-resolution studies of viral-host dynamics, especially in cell systems expressing low ACE2.
    • Facilitates the development of cardiovascular disease models that also account for infectious comorbidities, such as those seen in COVID-19 patients.

    This application domain remains underexplored in earlier articles, such as “Angiotensin 1/2 (2-7): Unlocking Precision in Vascular Re...”, which focus largely on traditional cardiovascular endpoints. Our present focus on spike–AXL interaction and its implications for translational infectious disease research marks a significant content differentiation.

    Methodological Considerations and Best Practices

    For optimal experimental results:

    1. Use freshly prepared solutions, as recommended for short-term experiments.
    2. Validate activity via HPLC and MS to ensure high-purity standards are met.
    3. Employ complementary RAS peptides for pathway mapping and comparative assays.

    These best practices ensure reproducibility and facilitate advanced mechanistic studies in both cardiovascular and infectious disease contexts.

    Expanding the Research Horizon: Future Directions

    Integrative Disease Modeling

    Given its dual utility in cardiovascular and viral research, Angiotensin 1/2 (2-7) is uniquely positioned for integrative disease modeling—bridging the gap between classical hypertension studies and the new frontier of host-pathogen interaction research. Its ability to modulate both vascular tone and viral receptor binding underscores the need for interdisciplinary approaches leveraging this peptide as a molecular probe.

    Beyond the Current Literature

    While prior content, such as “Angiotensin 1/2 (2-7): Mechanistic Insight and Strategic ...”, provides actionable guidance for cardiovascular and viral pathogenesis research, our article advances the field by:

    • Detailing the mechanistic basis for the peptide’s selective enhancement of spike–AXL binding.
    • Proposing new experimental paradigms that exploit these insights for rapid screening of therapeutic candidates or mechanistic probes.
    • Highlighting the translational potential of Angiotensin 1/2 (2-7) in multi-system disease models.

    Conclusion and Future Outlook

    Angiotensin 1/2 (2-7) stands at the intersection of cardiovascular and infectious disease research, providing a versatile, high-purity peptide tool for advanced mechanistic studies. By integrating classic and emerging functions—ranging from aldosterone release stimulation and blood pressure modulation to enhancement of viral spike–receptor interactions—this peptide opens new research frontiers. Leveraging its unique properties as an angiotensin-converting enzyme substrate and molecular modulator, future work should focus on multi-modal disease modeling and therapeutic innovation.

    For researchers seeking to extend the boundaries of RAS and infectious disease study, the high-purity Angiotensin 1/2 (2-7) reagent offers both reliability and translational relevance. For a broader strategic perspective, review prior content such as “Angiotensin 1/2 (2-7): Mechanistic Insights and Strategic...” and “Angiotensin 1/2 (2-7): Advanced Perspectives in Cardiovas...”; our present work builds upon these by focusing on the molecular mechanisms and translational innovations that will define the next era of peptide-based research.